ATR on NYSE

Aptar

Pharmaceutical Packaging Firm

AptarGroup, Inc., also known as Aptar, is a United States–based global manufacturer of consumer dispensing packaging and drug delivery devices. The group has manufacturing operations in 18 countries.3 Its shares trade on NYSE under the symbol ATR.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

1992Founded1

Compare with Entegris, Newell Brands or Armstrong World Industries, or pick any stock.

  • TickerATR on NYSE1
  • IndustryPlastics Products, NEC1
  • HeadquartersCrystal Lake1
  • Legal formDelaware corporation1
  • Incorporated inDE5
  • Business address265 Exchange Drive, Suite 301, Crystal Lake, Il 600145
  • Filer categoryLarge accelerated filer5
  • LEIVNPEQDQFAA7IY1T2PX434
  • StatusActive4
  • LEI statusIssued and current4
  • Registered addressc/o COGENCY GLOBAL INC., 850 New Burton Road Suite 201, 19904 Dover, United States4
  • Registered withDivision of Corporations, Department of State, 23086064

AptarGroup, Inc., also known as Aptar, is a United States–based global manufacturer of consumer dispensing packaging and drug delivery devices. The group has manufacturing operations in 18 countries.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

13.3%Operating margin8
10.4%Net margin8
5.4%Revenue growth, 20258
14.7%Return on equity8
$299.6MFree cash flow8

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Business segments

Pharma brought in 46% of the revenue Aptar broke down this way in fiscal 2025.

  1. Pharma$1.7B846%up 6% from 2024
  2. Beauty$1.3B835%up 7% from 2024
  3. Closures$736.9M819%up 2% from 2024
Business segments by year
Business segments202320242025
Pharma$1.5B$1.6B$1.7B
Beauty$1.3B$1.2B$1.3B
Closures$706.8M$721.6M$736.9M

Regions

Other Europe brought in 23% of the revenue Aptar broke down this way in fiscal 2025.

  1. Other Europe$788.1M823%up 5% from 2024
  2. Other Foreign Countries$648.8M819%up 5% from 2024
  3. France$513.3M815%up 3% from 2024
  4. Asia$443.9M813%up 16% from 2024
  5. Latin America$296.4M89%up 4% from 2024
  6. Italy$201.9M86%up 12% from 2024
  7. Spain$195.4M86%up 14% from 2024
  8. China$194.4M86%up 25% from 2024
  9. Germany$163.9M85%down 4% from 2024
Regions by year
Regions202320242025
Other Europe$727.7M$748.3M$788.1M
Other Foreign Countries$586.5M$619.6M$648.8M
France$541.3M$499.8M$513.3M
Asia$341.4M$381.3M$443.9M
Latin America$289.2M$286.2M$296.4M
Italy$200.8M$180.1M$201.9M
Spain$175.1M$171.8M$195.4M
China$146.0M$155.5M$194.4M
Germany$160.8M$169.9M$163.9M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development3¢$105.1M
  • Other costs84¢$3.2B
  • Income tax3¢$98.9M
  • Profit10¢$392.8M

Out of $3.8B in revenue.8

Where each dollar of operating cash went, fiscal 2025

  • Capital spending36¢$270.4M
  • Dividends paid16¢$120.8M
  • Share buybacks48¢$365.0M

Out of $570.0M of cash from operations. Spending exceeded cash from operations; the rest came from savings or borrowing.8

Financial statements

Revenue91011128$3.8B in 2025+32% since 2019
0$1.0B$2.0B$3.0B$4.0B2019: $2.9B$2.9B20192020: $2.9B$2.9B2020+2%2021: $3.2B$3.2B2021+10%2022: $3.3B$3.3B2022+3%2023: $3.5B$3.5B2023+5%2024: $3.6B$3.6B2024+3%2025: $3.8B$3.8B2025+5%
Gross profit13$906.0M in 2020+4% since 2019
0$250.0M$500.0M$750.0M$1.0B2019: $874.4M$874.4M20192020: $906.0M$906.0M2020+4%
Operating income91011128$501.0M in 2025+35% since 2019
0$200.0M$400.0M$600.0M2019: $371.7M$371.7M20192020: $339.5M$339.5M2020−9%2021: $347.3M$347.3M2021+2%2022: $379.3M$379.3M2022+9%2023: $404.0M$404.0M2023+7%2024: $496.5M$496.5M2024+23%2025: $501.0M$501.0M2025+1%
Net income91011128$392.8M in 2025+62% since 2019
0$100.0M$200.0M$300.0M$400.0M2019: $242.2M$242.2M20192020: $214.0M$214.0M2020−12%2021: $244.1M$244.1M2021+14%2022: $239.3M$239.3M2022−2%2023: $284.5M$284.5M2023+19%2024: $374.5M$374.5M2024+32%2025: $392.8M$392.8M2025+5%

Every line of the income statement as filed: the last 3 fiscal years, latest first.8

Period ending2025-12-312024-12-312023-12-31
Net Sales$3.8B$3.6B$3.5B
Cost of Sales (exclusive of depreciation and amortization):$2.4B$2.2B$2.2B
Selling, Research & Development and Administrative:$606.5M$582.2M$565.8M
Depreciation and amortization$287.4M$263.8M$248.6M
Restructuring initiatives$9.8M$13.0M$45.0M
Total Operating Expenses$3.3B$3.1B$3.1B
Operating Income$501.0M$496.5M$404.0M
Interest expense-$52.7M-$43.9M-$40.4M
Interest income$11.7M$12.1M$4.4M
Net investment (loss) gain-$483.0K$1.7M$1.4M
Equity in results of affiliates$7.4M$87.0K$2.2M
Gain from remeasurement of equity method investment$26.5M$0$0
Miscellaneous (expense) income, net-$2.0M$3.3M$3.2M
Total Other Expense-$9.7M-$26.7M-$29.2M
Income before Income Taxes$491.4M$469.8M$374.8M
Provision for Income Taxes$98.9M$95.6M$90.6M
Net Income$392.5M$374.2M$284.2M
Net Loss Attributable to Noncontrolling Interests$206.0K$363.0K$311.0K
Net Loss Attributable to Redeemable Noncontrolling Interests$86.0K$0$0
Net Income Attributable to AptarGroup, Inc.$392.8M$374.5M$284.5M
Basic (in dollars per share)$5.97$5.65$4.34
Diluted (in dollars per share)$5.89$5.53$4.25
Dividends per Common Share (in dollars per share)$1.83$1.72$1.58

Compare Aptar with another company

Corporate structure

Aptar sits at the top of its group. 107 entities, 26 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Aptar

  • Aptar Crystal Lake, Illinois, United States
    • Aptar (France ) Le Neubourg, France
    • 7M Valf Sanayi Ve Mühendislik Anonim Sirketi Subsidiary · Turkey
    • AIGE LLC Subsidiary · Delaware, United States
    • Aptar (China) Investment Co., Ltd. Subsidiary · China
    • Aptar (Guangzhou) Dispensing Systems Co., Ltd. Subsidiary · China
    • Aptar (Thailand) Ltd. Subsidiary · Thailand
    • Aptar Andina SAS Subsidiary · Colombia
    • Aptar Argentina S.A. Subsidiary · Argentina
    • Aptar Ballinasloe Limited Subsidiary · Ireland
    • Aptar Cali SAS Subsidiary · Colombia
    • Aptar Czech Republic s.r.o. Subsidiary · Čkyně, Czechia
    • Aptar Digital Health, LLC Subsidiary · Delaware, United States
    • Aptar Do Brasil Embalagens Ltda. Subsidiary · Brazil
    • Aptar Dortmund GmbH Subsidiary · Dortmund, Germany
    • APTAR EL MARQUES, S. de R.L. de C.V. (APTAR EL MARQUÉS, S. de R.L. de C.V.) Subsidiary · El Marqués, Mexico
    • Aptar El Marqués S. de R.L. de C.V. Subsidiary · Mexico
    • Aptar Europe Holding SAS Subsidiary · Louveciennes, France
    • Aptar France S.A.S. Subsidiary · France
    • Aptar Freyung GmbH Subsidiary · Freyung, Germany
    • Aptar Global Business Services CZ s.r.o. Subsidiary · Ceske Budejovice, Czechia
    • Aptar Government, LLC Subsidiary · Delaware, United States
    • Aptar Heng Yu (Weihai) Medical Device Co., Ltd. Subsidiary · China
    • Aptar Investment, LLC Subsidiary · Delaware, United States
    • Aptar Istanbul Ambalaj Üretim Ticaret ve Sanayi A.Ş Subsidiary · Turkey
    • APTAR ITALIA S.P.A. Subsidiary · San Giovanni Teatino, Italy
    • and 81 more

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Aptar reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Land$31.5M8 Dec 31, 2025$28.2M8 Dec 31, 2024+11.8%
Buildings and improvements$885.9M8 Dec 31, 2025$751.8M8 Dec 31, 2024+17.8%
Machinery and equipment$3.7B8 Dec 31, 2025$3.1B8 Dec 31, 2024+16.4%
Property and equipment, net$1.7B8 Dec 31, 2025$1.4B8 Dec 31, 2024+15.8%
Finance-lease assets$29.0M8 Dec 31, 2025$30.2M8 Dec 31, 2024−4.0%
Operating-lease assets (leased space)$65.7M8 Dec 31, 2025$64.2M8 Dec 31, 2024+2.3%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$402.4M8 Dec 31, 2025$223.8M8 Dec 31, 2024+79.8%
Marketable securities, current$7.1M8 Dec 31, 2025$2.3M8 Dec 31, 2024+204.2%
Long-term investments$131.0M8 Dec 31, 2025$146.3M8 Dec 31, 2024−10.4%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$1.1B8 Dec 31, 2025$936.3M8 Dec 31, 2024+15.1%
Finite-lived intangibles, gross$588.3M8 Dec 31, 2025$528.5M8 Dec 31, 2024+11.3%
Accumulated amortization$332.9M8 Dec 31, 2025$273.7M8 Dec 31, 2024+21.6%
Finite-lived intangibles, net$255.3M8 Dec 31, 2025$254.8M8 Dec 31, 2024+0.2%

Inventory

ItemLatestA year beforeChange
Inventory, total$537.8M8 Dec 31, 2025$461.8M8 Dec 31, 2024+16.5%
Raw materials$152.6M8 Dec 31, 2025$133.9M8 Dec 31, 2024+14.0%
Work in process$194.2M8 Dec 31, 2025$161.3M8 Dec 31, 2024+20.3%
Finished goods$191.1M8 Dec 31, 2025$166.6M8 Dec 31, 2024+14.7%

Properties, in its own words

We lease or own our principal offices and manufacturing facilities. None of the owned principal properties is subject to a lien or other encumbrance material to our operations. We believe that existing operating leases will be renegotiated as they expire, will be acquired through purchase options or that suitable alternative properties will be leased on acceptable terms. We consider the condition and extent of utilization of our manufacturing facilities and other properties to be generally good, and the capacity of our plants to be adequate for the needs of our business. We manufacture products in 57 locations, with 14 of those facilities serving two segments and one serving all three of our segments as of December 31, 2025. The locations of our manufacturing facilities, by geographic region/country, are set forth below:

Geographic Region/Country · Number of Manufacturing Facilities · Pharma Manufacturing Facilities · Beauty Manufacturing Facilities · Closures Manufacturing Facilities

The rest of Item 2

France · 11 · 6 · 7 · 0

Germany · 6 · 4 · 4 · 1

Rest of Europe/United Kingdom · 8 · 2 · 3 · 4

North America · 9 · 5 · 3 · 5

Latin America · 9 · 2 · 6 · 2

China · 10 · 3 · 3 · 4

Other Asia/Middle East · 4 · 1 · 2 · 3

Total · 57 · 23 · 28 · 19

Our head corporate office is located in Crystal Lake, Illinois. We also have sales, service facilities, and corporate offices in locations in addition to those listed above.

Item 2 of the 10-K filed Feb 6, 2026.16

The story

The company began as Werner Die & Stamping in Cary, Illinois, in 1946 and later incorporated as AptarGroup in 1992. Aptar originally developed spray valves and pumps for consumer and household products. The company later began producing nasal administration and pulmonary drug delivery devices such as nasal spray systems and metered-dose inhaler valves. Biotech and pharmaceutical companies use Aptar's different Unidose and Bidose devices for the single or two-shot intranasal delivery of different medicines.

In 2016, Aptar announced that it provided the delivery system for Adapt Pharma's Narcan. Narcan is a naloxone hydrochloride nasal spray used as an emergency treatment for opioid overdoses. Aptar's liquid spray drug delivery technology platform works as a ready-to-use, single-shot, unit-dose system for Narcan. It was the first FDA approved nasally administered, ready-to-use medication used to reverse the effects of an opioid overdose. Narcan does not require any assembly, medical training, or needle injection.

In 2016, Aptar entered into an agreement with Becton Dickinson & Company to develop new self-injection devices.

Aptar entered into an agreement in 2016 with Propeller Health Partners to develop a digitally connected medication inhaler. The company made an investment in Propeller Health Partners (now part of Resmed) in 2018.

In July 2019, the FDA-approved Aptar Pharma's Unidose Powder System as the first intranasally-delivered, needle-free rescue treatment for severe hypoglycemia.

In 2020, during the COVID-19 pandemic, Aptar invested in new tools to accelerate its molding equipment and assembly machines for pumps, but it still wasn't enough to keep up with demand.

Acquisitions

In 2012, Aptar acquired Stelmi, a manufacturer of elastomer primary packaging components. In 2016, Aptar acquired Mega Airless, a manufacturer of airless packaging. In 2018, Aptar acquired CSP Technologies, a material science company that manufactures active packaging.

In June 2019, Aptar acquired two companies, Nanopharm and Gateway Analytical. In November 2019, the company acquired Noble International, which specializes in training devices and patient onboarding. In February 2020, Aptar acquired FusionPKG, a makeup packaging company.

Read the full text

In November 2020, the company acquired the digital respiratory health company Cohero Health.

In July 2021 Aptar acquired the digital therapeutics company, Voluntis (ENXTPA: ALVTX), and 80% of the equity interests of Weihai Hengyu Medical Products Co., Ltd., a Chinese manufacturer of elastomeric and plastic components used in injectable drug delivery.

From Wikipedia’s article on AptarGroup, shared under CC BY-SA 4.0.6

Leadership

Who has led Aptar, and when. Pick a name to see everywhere that person has worked.

Board members and other officers (40)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • 7M Valf Sanayi Ve Mühendislik Anonim Sirketi Turkey7
  • AIGE LLC Delaware7
  • Aptar (China) Investment Co., Ltd. China7
  • Aptar (Guangzhou) Dispensing Systems Co., Ltd. China7
  • Aptar (Thailand) Ltd. Thailand7
  • Aptar Andina SAS Colombia7
  • Aptar Argentina S.A. Argentina7
  • Aptar Ballinasloe Limited Ireland7
  • Aptar Cali SAS Colombia7
  • Aptar Czech Republic S.r.o. Czech Republic7
  • Aptar Digital Health, LLC Delaware7
  • Aptar Do Brasil Embalagens Ltda. Brazil7
  • Aptar Dortmund GmbH Germany7
  • Aptar El Marqués S. de R.L. de C.V. Mexico7
  • Aptar Europe Holding SAS France7
  • Aptar France S.A.S. France7
  • Aptar Freyung GmbH Germany7
  • Aptar Global Business Services CZ S.r.o. Czech Republic7
  • Aptar Government, LLC Delaware7
  • Aptar Heng Yu (Weihai) Medical Device Co., Ltd. China7
  • Aptar Investment, LLC Delaware7
  • Aptar Istanbul Ambalaj Üretim Ticaret ve Sanayi A.Ş Turkey7
  • Aptar Italia S.p.A. Italy7
  • Aptar Japan Kabushiki Kaisha (K.K) Japan7
All 99 listed subsidiaries
  • Aptar Menden GmbH Germany7
  • Aptar Mezzovico S.A. Switzerland7
  • Aptar Oyonnax S.A.S. France7
  • Aptar Packaging Technology (Daqing) Co., LTD China7
  • Aptar Packaging Technology (Harbin) Co., LTD China7
  • Aptar Pharma India Private Limited India7
  • Aptar Pharma Services, Inc. Delaware7
  • Aptar Queretaro S. de R.L. de C.V. Mexico7
  • Aptar Radolfzell GmbH Germany7
  • Aptar Services S.A.S. France7
  • Aptar Singapore PTE. Ltd. Singapore7
  • Aptar Stelmi SAS France7
  • Aptar Suzhou Dispensing Systems Co. Ltd. China7
  • Aptar Torello, S.A. Spain7
  • Aptar UK Ltd. United Kingdom7
  • Aptar Ventures II LLC Delaware7
  • Aptar Ventures LLC Delaware7
  • Aptar Villingen GmbH Germany7
  • AptarGroup International Holding S.a.r.l. Luxembourg7
  • AptarGroup International L.L.C. Delaware7
  • Aptargroup Holding GmbH Germany7
  • Aptargroup UK Holdings Limited United Kingdom7
  • Beauty (Suzhou) Plastic Technology Co., Ltd. China7
  • Beauty Jiangsu Packaging Technology Co., Ltd. China7
  • CSP Technologies SAS France7
  • CSP Technologies, Inc. Delaware7
  • Desotec GmbH Germany7
  • Dianosic SAS France7
  • Diary Daily Chemicals (Shanghai) Co., Ltd. China7
  • Fusion Accelerate LLC Texas7
  • Fusion Packaging I, LLC Delaware7
  • Fusion Packaging Trading (Shanghai) Co. LTD China7
  • Gateway Analytical, LLC Delaware7
  • Genia Medical, Inc. Florida7
  • Gensight, LLC Florida7
  • Graphocolor S.A.S. France7
  • Gulf Closures W.L.L. Bahrain7
  • Innovation Packaging Co., Ltd. Hong Kong7
  • Innovation Packaging USA Co., Ltd. California7
  • JBCB Holdings, LLC Florida7
  • Jiwu (Shanghai) Pharmaceutical Technology Co., Ltd. China7
  • Kafert Suzhou Precision Mold Technology Co., Ltd. China7
  • Kali Care, Inc. Delaware7
  • Loop Global Holdings, LLC Delaware7
  • MIWA Technologies, A.S. Czech Republic7
  • Mega Airless Asia Limited Hong Kong7
  • Mufei Tongchuang (Chongqing) Technology Co., Ltd. China7
  • NanoPharm Ltd. United Kingdom7
  • Navia Life Care Private Limited India7
  • Ningbo Jiecheng International Trading Co., Ltd. China7
  • Ningbo Jinyu International Trading Co., Ltd. China7
  • Ningbo Jinyu Technology Industry Co., Ltd. China7
  • Ningbo Jinyuan Packaging Co., Ltd. China7
  • Ningbo RO China7
  • Noble International, LLC Delaware7
  • OOO Aptar Vladimir Russia7
  • PT. Aptar Indonesia Indonesia7
  • Philson, Inc. Connecticut7
  • Purecycle Technologies, LLC Delaware7
  • RE-Company SA Switzerland7
  • REBOUL SAS France7
  • Seaquist Canada Ltd. Canada7
  • Seaquist Closures France S.A.S. France7
  • Shanghai Shuo Mao Network Technology Co. Ltd. China7
  • Shanghai Sonmol Medical Equipment Co., Ltd. China7
  • Shuo Mao Damai (Chongqing) Technology Co. Ltd. China7
  • Shuo Mao Enterprise Management Center (LLP) China7
  • Shuo Mao Tongchuang (Chongqing) Technology Co., Ltd. China7
  • Shuo Mao Trading Co., Ltd. China7
  • Shuo Mao Yuanjing (Chongqing) Technology Co., Ltd. China7
  • Sommaplast Industria E Comercio Ltda Brazil7
  • Suqian Hsing Kwang Metal Technology Co., Ltd. China7
  • Suzhou Hsing Kwang Precision Hardware Products Co., Ltd. China7
  • Voluntis, SAS France7
  • Yangi AB Sweden7

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • APTARGROUP INCOct 17, 1995 to Dec 10, 20215

Timeline

  1. Sep 21, 20268-K Regulation FD disclosure72
  2. Sep 10, 20268-K Executive or director change73
  3. Sep 1, 20268-K Executive or director change74
  4. Jul 30, 20268-K Results of operations75
  5. May 13, 20268-K Executive or director change76
  6. May 7, 20268-K Shareholder vote77
  7. May 4, 2026New chief executive Gael Touya becomes CEO17
  8. Apr 30, 20268-K Results of operations78
  9. Mar 17, 20268-K Executive or director change79
  10. Feb 5, 20268-K Results of operations80
  11. Nov 20, 20258-K Entered a material agreement; Other events81
  12. Oct 30, 20258-K Results of operations82
  13. Jul 31, 20258-K Results of operations83
  14. Feb 6, 2017New chief executive Stephan B. Tanda becomes CEO18
  15. Jan 12, 2012New chief executive Stephen J. Hagge becomes CEO19
  16. Jan 19, 2006New chief executive Carl A. Siebel becomes CEO20
  17. 1992Founded Founded1

Calendar

Coming up

  1. Oct 29, 2026 · After the closeReports results for the quarter ending Sep/2026 A year earlier it reported $1.62 a share, on Oct 30, 2025.84

When it reported results

  1. Jul 30, 2026Reported quarterly or annual results75
  2. Apr 30, 2026Reported quarterly or annual results78
  3. Feb 5, 2026Reported quarterly or annual results80
  4. Oct 30, 2025Reported quarterly or annual results82
  5. Jul 31, 2025Reported quarterly or annual results83
  6. May 1, 2025Reported quarterly or annual results85
  7. Feb 6, 2025Reported quarterly or annual results86
  8. Oct 24, 2024Reported quarterly or annual results87

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

517 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 43 major events, 338 insider forms, 20 large holders, 96 other. The latest 20:

  1. Sep 21, 20268-K EDGAR
  2. Sep 11, 20263 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  3. Sep 10, 20268-K EDGAR
  4. Sep 3, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  5. Sep 2, 2026144 EDGAR
  6. Sep 2, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  7. Sep 1, 20268-K EDGAR
  8. Aug 28, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  9. Aug 27, 2026144 EDGAR
  10. Aug 12, 2026SCHEDULE 13G/A EDGAR
  11. Aug 5, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  12. Aug 4, 2026144 EDGAR
  13. Aug 4, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  14. Aug 3, 2026144 EDGAR
  15. Aug 3, 2026144 EDGAR
  16. Aug 3, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  17. Jul 31, 202610-Q EDGAR
  18. Jul 30, 20268-K EDGAR
  19. Jul 17, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  20. Jul 17, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR

The 517 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

63 open-market trades by officers, directors and large owners since October 2021: 1 buys and 62 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 2, 2026Vinczeller ShielaChief Human Resources OfficerSale765$130.37$99.7KForm 4
Aug 27, 2026Touya GaelPresident and CEOSale3,740$133.76$500.3KForm 4
Aug 4, 2026Prieur MarcSegment PresidentSale3,500$136.26$476.9KForm 4
Aug 3, 2026Tanda Stephan B.President and CEOSale9,838$136.16$1.3MForm 4
Aug 3, 2026Tlili HediSegment PresidentSale8,854$135.00$1.2MForm 4
Jun 9, 2026Prieur MarcSegment PresidentSale5,000$115.58$577.9KForm 4
Jun 4, 2026Vinczeller ShielaChief Human Resources OfficerSale3,555$112.62$400.3KForm 4
May 26, 2026Gong XiangweiPresident, AsiaSale4,200$116.13$487.7KForm 4
May 7, 2026Hudson Irene ElizabethEVP and Chief Legal OfficerSale1,264$123.43$156.0KForm 4
Feb 18, 2026Touya GaelPresident and CEOSale3,500$141.35$494.7KForm 4
Feb 10, 2026Prieur MarcSegment PresidentSale2,000$137.81$275.6KForm 4
Dec 12, 2025Ackerman DanielInterim CAOSale15,000$121.23$1.8MForm 4
Sep 11, 2025Touya GaelPresident and CEOSale2,500$136.12$340.3KForm 4
Sep 5, 2025Vinczeller ShielaChief Human Resources OfficerSale1,167$137.97$161.0KForm 4
Jun 13, 2025Prieur MarcSegment PresidentSale2,000$152.80$305.6KForm 4
Jun 10, 2025Chainey KimberlyEVP and Chief Legal OfficerSale1,671$152.79$255.3KForm 4
Jun 6, 2025Touya GaelPresident and CEOSale3,300$152.63$503.7KForm 4
May 22, 2025Gong XiangweiPresident, AsiaSale7,000$156.49$1.1MForm 4
May 20, 2025Prieur MarcSegment PresidentSale6,000$158.34$950.0KForm 4
May 16, 2025Tlili HediSegment PresidentSale3,614$155.96$563.6KForm 4

All 63 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.6,137,894$768.5M0.0%+54,376
State Farm Mutual Automobile Insurance Co4,744,564$594.0M0.4%No change
Vanguard Portfolio Management LLC3,638,724$455.6M0.0%−129,048
Morgan Stanley3,523,908$441.2M0.0%+148,112
Vanguard Capital Management LLC2,893,751$362.3M0.0%+8,454
State Street Corp2,863,390$358.5M0.0%+78,851
Victory Capital Management Inc2,554,561$319.8M0.2%+135,677
Geode Capital Management, LLC1,747,815$218.9M0.0%+53,740
Dimensional Fund Advisors LP1,741,294$218.0M0.0%+236,821
Neuberger Berman Group LLC1,548,824$193.9M0.1%+374,287
Fiduciary Management Inc /wi/1,423,771$178.3M2.5%+171,433
River Road Asset Management, LLC1,350,700$169.1M1.9%+173,697
Boston Trust Walden Corp1,303,726$163.2M1.2%−45,763
Fmr LLC1,073,810$134.4M0.0%+45,659
Northern Trust Corp1,070,632$134.0M0.0%+2,867
London Co Of Virginia793,033$99.3M0.6%−35,747
Quantinno Capital Management LP736,351$92.2M0.1%+387,422
Aqr Capital Management LLC680,207$84.7M0.0%−549,071
Atlas FRM LLC670,000$83.9M3.6%+320,000
Norges Bank649,607$81.3M0.0%New
Williams Jones Wealth Management, LLC.570,888$71.5M0.8%−16,448
First Trust Advisors LP545,629$68.3M0.0%+7,075
Charles Schwab Investment Management Inc477,508$59.8M0.0%+12,628
Bank of New York Mellon Corp477,462$59.8M0.0%−28,041
American Century Companies Inc462,989$58.0M0.0%+428,119

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

1 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Jun 24, 2025Lisa C. McClainRepublican, HouseBuy$1,001 - $15,000−46.3%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

SEC filer profile

How Aptar is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAPTARGROUP, INC.2
  • CIK0000896622
  • Employer ID (EIN)36-385310316
  • Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company16
  • Incorporated inDelaware16
  • Fiscal year endsDecember 312
  • Industry code (SIC)3089 Plastics Products, NEC2
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance2
  • Business address265 Exchange Drive, Suite 301, Crystal Lake, IL 600142
  • Phone81547704242
  • Shares outstanding63,581,129 as of Jul 27, 202615
  • Public float$10.3B as of Jun 30, 202516
  • AuditorPricewaterhouseCoopers LLP, Chicago, Illinois PCAOB ID 238; it also attests to the company’s internal control over financial reporting16
  • On EDGAR sinceMay 26, 19952
  • Filings1,967 in all: 4 (1,263), 8-K (165), 10-Q (91), SC 13G/A (90), 144 (58), 3 (35), 11-K (31), DEF 14A (30)2
    All 38 form types

    SC 13G (30), 10-K (29), 4/A (29), ARS (18), S-8 (15), SC 13D/A (14), SD (13), UPLOAD (8), DEFA14A (7), 424B5 (4), 5 (4), CORRESP (4), SC 13D (4), PRE 14A (3), SCHEDULE 13G/A (3), FWP (2), S-3 (2), S-3ASR (2), SCHEDULE 13G (2), 10-K405 (1), 25-NSE (1), 305B2 (1), 424B1 (1), 8-A12B (1), 8-K/A (1), CERTNYS (1), CT ORDER (1), DEFR14A (1), RW (1), S-3/A (1)

  • Latest filingsAnnual report (10-K) Feb 6, 2026
    Quarterly report (10-Q) Jul 31, 2026
    Proxy statement (DEF 14A) Mar 27, 2026
    Latest 8-K (8-K) Sep 21, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, $.01 par valueATRNew York Stock Exchange

From the cover page of the 10-K filed Feb 6, 2026 (Section 12(b) of the Exchange Act).16

Risk factors and legal proceedings

The risks Aptar names in Item 1A of its 10-K filed Feb 6, 2026: 24 risks under these headings, as written.16

  • Risks Related to Our Operations and Industry
  • If there is deterioration in economic conditions, our business and operating results could be materially adversely impacted.
  • Geopolitical conditions, including trade disputes and acts of war or terrorism, could have a material adverse effect on our operations and financial results.
  • Significant tariffs or other restrictions imposed on foreign imports by the U.S. and related countermeasures taken by impacted foreign countries could have a material adverse effect on our operations and financial results.
  • Increased global cybersecurity threats and more sophisticated, targeted computer crime, as well as failures or disruptions of our information technology systems, could pose a risk to our operations.
  • We face strong global competition and our market share could decline.
  • In difficult market conditions, our fixed costs structure combined with potentially lower revenues may negatively impact our results.
  • Our ability to adequately source materials including those from a single supplier or from a single manufacturing location, could adversely impact our ability to deliver our products.
  • A material failure or disruption at one or more of our manufacturing facilities could adversely affect our ability to generate sales and meet customer demand.
  • Global health crises, epidemics and pandemics may adversely affect our business, and financial condition and results of operations.
  • The success or failure of our customers’ products, particularly in the pharmaceutical market, may materially affect our operating results and financial condition.
  • Higher raw material costs and other inputs and an inability to offset these higher costs with price increases may materially adversely affect our operating results and financial condition.
The other 13 risks
  • If disputes with our unions arise, or if our unionized workers engage in a strike or other work stoppage, or if our suppliers engage in a strike or other work stoppage, we could experience a significant disruption of operations.
  • If our integration of acquisitions or significant capital investments fail to generate expected returns, our financial performance may suffer.
  • Risks Related to Financial, Legal and Regulatory Matters
  • We have foreign currency translation and transaction risks that may materially adversely affect our operating results.
  • We have approximately $1.08 billion in recorded goodwill at December 31, 2025, and changes in future business conditions could cause this asset to become impaired, requiring write-downs that would reduce our operating income.
  • We are subject to a variety of laws and regulations and changes in, or failure to comply with, these laws or regulations could have an adverse impact on the Company’s reputation, business and results of operations.
  • We are exposed to risks from lawsuits and claims, including product liability claims, as well as investigations, audits and other proceedings, which may result in substantial costs and expenses or interruption of our normal business operations.
  • Government regulation on environmental matters, including recycling or environmental sustainability policies could impact our business.
  • Future government regulations of healthcare cost containment policies may impact our pharmaceutical sales.
  • Interest rate volatility could increase our borrowing costs.
  • We could be subject to changes in tax rates, the adoption of new tax legislation or rules or exposure to additional tax liabilities.
  • Our financial performance could be impacted by loss of royalty revenues.
  • General Risk Factors
  • Global climate change and legal, regulatory, or market measures to address climate change, may negatively affect our business, operations and financial results.
  • Ownership by Certain Significant Stockholders.

Legal proceedings

We are subject to a number of lawsuits and claims both actual and potential in nature. While management believes the resolution of these claims and lawsuits will not have a material adverse effect on our financial position or results of operations or cash flows, claims and legal proceedings are subject to inherent uncertainties, and unfavorable outcomes could occur that could include amounts in excess of any accruals which management has established. Were such unfavorable final outcomes to occur, it is possible that they could have a material adverse effect on our financial position, results of operations and cash flows. For information regarding these and other contingencies, please refer to Note 13 – Commitments and Contingencies in Part II, Item 8 – Financial Statements and Supplementary Data.

The opening of Item 3, Legal Proceedings.16

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81
  82. 82
  83. 83
  84. 84
  85. 85
  86. 86
  87. 87
  88. 88
  89. 89
  90. 90
  91. 91
  92. 92
  93. 93
  94. 94